Generic Industry Wants More Guidance On Demonstrating Equivalence Of Drug-Device Combinations
Firms want US FDA to better address how generic drug manufacturers can demonstrate similarity to innovator drug-device combination products.
You may also be interested in...
But US FDA officials say brand vs. generic product differences won't be appropriate in all cases and patient misuse remains a concern.
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'